[go: up one dir, main page]

WO2024049361A1 - Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates - Google Patents

Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates Download PDF

Info

Publication number
WO2024049361A1
WO2024049361A1 PCT/TH2022/000032 TH2022000032W WO2024049361A1 WO 2024049361 A1 WO2024049361 A1 WO 2024049361A1 TH 2022000032 W TH2022000032 W TH 2022000032W WO 2024049361 A1 WO2024049361 A1 WO 2024049361A1
Authority
WO
WIPO (PCT)
Prior art keywords
active substances
cannabinoid
based compositions
acid
leaves
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TH2022/000032
Other languages
French (fr)
Inventor
Chokchai KWANPICHIT
Narongsak Tonmukayakul
Voravee THUMCHA
Surachavadi BURANAPIN
Rita TRAIMANEE
Krit SRIWAROM
Pudit BURANAPIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fair Med Thailand Co Ltd
Original Assignee
Fair Med Thailand Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fair Med Thailand Co Ltd filed Critical Fair Med Thailand Co Ltd
Priority to AU2022476802A priority Critical patent/AU2022476802A1/en
Priority to PCT/TH2022/000032 priority patent/WO2024049361A1/en
Publication of WO2024049361A1 publication Critical patent/WO2024049361A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • the invention relates to cannabinoid-based compositions comprising active substances from cannabis and/or hemp in conjunction with active substances from other genera, in combination for wounds healing and thereof.
  • wounds from injuries are uncontrollable and difficult to prevent, especially for the elderly or patients with medical condition or low immunity that small or large wounds, or scratching that cause wounds on the skin are more prone to incidence while some wounds can heal on their own.
  • wound dressing or wound care is of paramount importance, as can be seen in many products that help promote wound care in the form of equipment, materials, products, from devices or products for wound care and dressings, external medicine for wounds, bandages, and products to apply when the wound starts to dry so that the wound heals without scarring and it helps strengthen the skin cells in the area, as well as provide an even skin tone.
  • Another important aspect of wound healing is to prevent wound infection because if the wound gets infected, in addition to a longer duration of treatment, the wound may spread widely and damage the skin tissue. However, if the infection is severe or chronic, it can be widespread and difficult to heal, which may even result in the need to cut off some of the more damaged tissue. To prevent further skin damage from spreading to other areas, treatments to prevent wound infection include using herbal remedies directly and herbal medicine recipes that help in healing wounds to heal faster. According to the examination, it has been found that some pieces of work are applying for protection and are close to some composition as follows:
  • the Thai Petty Patent Application No. 1303000684 mentions a pharmaceutical composition for reducing the number of pathogens in infected wounds and wound healing with nutgall extract as an element by developing active substances extracted from nutgalls into a solution for use, wipe, apply or drop on wounds, especially chronic infected wounds in order to reduce or replace the use of alcohol in the treatment of chronic wound infections.
  • the Thai Petty Patent Application No. 1303000684 mentions a pharmaceutical composition for reducing the number of pathogens in infected wounds and wound healing with nutgall extract as an element by developing active substances extracted from nutgalls into a solution for use, wipe, apply or drop on wounds, especially chronic infected wounds in order to reduce or replace the use of alcohol in the treatment of chronic wound infections.
  • 1603001846 refers to a cream containing herbal extracts containing false daisy extract, mangosteen peel extract, Gotu Kola extract mixed with sodium lauryl sulfate, propylene glycol, stearyl alcohol, cetyl alcohol, coconut oil, concentrated parabens, distilled water, with the following cream manufacturing processes: by extracting false daisy, mangosteen peel, and Gotu Kola and mixing the extracts at the ratio of 3:1 :1 by weight and mix with other substances, stir, and adjust the pH to be between 6.0-7.0.
  • the United States patent publication no. US20210236687A1 refers to a woundmanagement component containing a combination of full-spectrum cannabinoids and at least one hemostatic agent. This includes a hemostasis-level astringent, a hemostasis level, and a hemostasis mechanism level.
  • the composition may also include at least a chemical infiltration enhancer that amplifies the absorption of cannabinoids, at least one topical drug to prolong the pharmacological activity of the cannabinoids, at least one antibacterial agent, and at least one antifungal agent, as well as means of delivery of wound management composition and kits.
  • the foreign patent publication no. WO2019202356A1 refers to the composition with cannabidiol supplementation and anti-inflammatory herbal extracts that inhibit COX (cyclooxygenase) and LOX (lipoxygenase), Psoralea Corylifolia or Betulin or rosemary leaf extract or licorice extract (Glycyrrhiza Glabra) with a small amount of cannabidiol of not more than 1.0% by volume.
  • the therapeutic effect of each herbal extract contains ingredients that can be used to heal skin inflammation.
  • compositions or products containing different herbs are used to treat different wounds to meet the needs of symptoms and wounds.
  • the inventor has invented a chemical compositions that contain active substances from cannabis or hemp for inhibiting bacteria that affects the skin in order to heal wounds, inhibit bacterial infection, help the blood to clot in order to allow the wounds to heal, and result in quick-drying and inhibiting skin irritation, particularly suitable for patients with low immunity, such as those with diabetes, shingles, and patients after surgery, etc.
  • the cannabinoid-based compositions are developed to provide unique properties to help the blood clot including the inhibition of bacterial infection.
  • the aforementioned compositions comprise active substances from cannabis or hemp together with active substances from other genera in appropriate quantities.
  • the preparation process of the aforementioned compositions involves the extraction and purification of the compositions to be chemical compositions suitable for healing and wound healing, especially for patients with bacterial skin infection, herpesvirus, psoriasis, postoperative wounds, diabetic wounds, skin imbalances and chronic inflammation.
  • the purpose of this invention is to provide a cannabinoid-based composition for medical use.
  • the unique property of such composition is function in coagulating blood together with inhibiting bacterial infection, which directly affects the healing of wounds, reducing inflammation and wound pain that may spread and damage the tissues of the wound. This makes the wound heal and the wound is covered to prevent getting pathogens faster.
  • the cannabinoid-based compositions for medical use contain active substances from cannabis or hemp that are effective against gram-positive, gram-negative bacteria and fungi that cause skin infections and can help reduce inflammation together with the composition of active substances of anisic acid, flavonoids, and triterpenoids that can be found from Siam weed leaves, False daisy leaves, centella asiatica, nutgall, etc., which are characterized in that they help stop bleeding, increase blood clotting to prevent and reduce blood loss from wounds, inhibit skin irritation and improve the effectiveness of wound healing, including reducing scarring.
  • the cannabinoid-based compositions include:
  • the appropriate amount of active substances from cannabis or hemp is 20-80% by weight, together with the active substances from other genera in the appropriate amount of 20-80% by weight.
  • composition requires the extraction process with hexane, ethyl acetate or other polar solvents such as acetone, ethanol, methanol, or water or a supercritical fluid extraction method, and then, to obtain a chemical mixture, it is subjected to a purification process by precipitation.
  • Active substances from cannabis or hemp may be selected from any one or more of cannabinoids comprising tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV) and cannabi di varin (CBDV), in combination thereof.
  • cannabinoids comprising tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV) and cannabi di varin (CBDV), in combination thereof.
  • Active substances from other genera may be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol, coumarin, false daisy leaves (Eclipta prostrata (L.) leaves, centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid, in combination thereof.
  • compositions were sent to the accredited laboratory for testing (In Vitro) to test their activity against bacteria and virus and they were found to have a beneficial effect on inhibiting gram-positive skin bacteria and herpesvirus with low concentrations for the production of the compositions for use in the treatment of patients by choosing to develop into a cream or gel form for ease of use, storage, and portability of users and with appropriate concentrations to test the side effects of skin wounds and surrounding wounds. All wounds were healed from the use of the compositions in a shorter time than patients expected compared to the length of time that patients had been treated with other medicines prior to receiving the compositions in this study, and there were no adverse effects on the wound healing and other surrounding skin as shown in the table:
  • the cannabinoid-based composition in cream or gel form can be used to treat patients with bacterial skin infection, herpesvirus, psoriasis, postoperative wounds, diabetic wounds, skin imbalances and chronic inflammation. It was observed that the rapid response phase of blood coagulation and wound healing improved within 3 to 7 days, and treatment was completed within 2-8 weeks, depending on the individual patient's condition. However, all of them recovered from the use of this composition in a shorter time than patients expected compared to the length of time patients were treated with other medicines before receiving the medicines in this study and had no side effects on the wound and other surrounding areas.
  • cannabinoid-based compositions comprise active substances that provide a direct effect on healing and inhibiting pathogens, balancing the skin system, and immune system, reducing inflammation, and reducing pain, through the endocannabinoid system and a group of ion channels on the cell membrane, TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation, the patients and their caregivers may use them to support patient care in conjunction with the current mainstream treatment. They also reduce the chance of organ loss such as in the feet and legs. In the case of patients with diabetic foot, they will recover faster and have fewer side effects from the disease. These are significant parts of gaining opportunities and holistic quality of life for patients and their caregivers. Best Mode of the Invention

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The cannabinoid -based compositions according to this invention are developed to provide unique properties to help the blood clot, including the inhibition of bacterial infection. The aforementioned compositions comprise active substances from cannabis or hemp together with active substances from other genera in appropriate quantities. The preparation process of the aforementioned compositions involves the extraction and purification of the compositions to be chemical compositions suitable for healing and wound healing, especially for patients with bacterial skin infection, herpes virus, psoriasis, postoperative wounds, diabetic wounds, skin imbalances and chronic inflammation.

Description

MIXTURES OF CANNABINOID-BASED COMPOSITIONS AND ACTIVE SUBSTANCES
FROM OTHER GENERA FOR MEDICAL APPLICATIONS AND ASSOCIATES
Field of the Invention
The invention relates to cannabinoid-based compositions comprising active substances from cannabis and/or hemp in conjunction with active substances from other genera, in combination for wounds healing and thereof.
Background of the Invention
Skin wounds from injuries are uncontrollable and difficult to prevent, especially for the elderly or patients with medical condition or low immunity that small or large wounds, or scratching that cause wounds on the skin are more prone to incidence while some wounds can heal on their own. However, as some wounds may require medication and take a long time to dry and heal completely, wound dressing or wound care is of paramount importance, as can be seen in many products that help promote wound care in the form of equipment, materials, products, from devices or products for wound care and dressings, external medicine for wounds, bandages, and products to apply when the wound starts to dry so that the wound heals without scarring and it helps strengthen the skin cells in the area, as well as provide an even skin tone.
Another important aspect of wound healing is to prevent wound infection because if the wound gets infected, in addition to a longer duration of treatment, the wound may spread widely and damage the skin tissue. However, if the infection is severe or chronic, it can be widespread and difficult to heal, which may even result in the need to cut off some of the more damaged tissue. To prevent further skin damage from spreading to other areas, treatments to prevent wound infection include using herbal remedies directly and herbal medicine recipes that help in healing wounds to heal faster. According to the examination, it has been found that some pieces of work are applying for protection and are close to some composition as follows:
The Thai Petty Patent Application No. 1303000684 mentions a pharmaceutical composition for reducing the number of pathogens in infected wounds and wound healing with nutgall extract as an element by developing active substances extracted from nutgalls into a solution for use, wipe, apply or drop on wounds, especially chronic infected wounds in order to reduce or replace the use of alcohol in the treatment of chronic wound infections. The Thai Petty Patent Application No. 1603001846 refers to a cream containing herbal extracts containing false daisy extract, mangosteen peel extract, Gotu Kola extract mixed with sodium lauryl sulfate, propylene glycol, stearyl alcohol, cetyl alcohol, coconut oil, concentrated parabens, distilled water, with the following cream manufacturing processes: by extracting false daisy, mangosteen peel, and Gotu Kola and mixing the extracts at the ratio of 3:1 :1 by weight and mix with other substances, stir, and adjust the pH to be between 6.0-7.0.
The United States patent publication no. US20210236687A1 refers to a woundmanagement component containing a combination of full-spectrum cannabinoids and at least one hemostatic agent. This includes a hemostasis-level astringent, a hemostasis level, and a hemostasis mechanism level. The composition may also include at least a chemical infiltration enhancer that amplifies the absorption of cannabinoids, at least one topical drug to prolong the pharmacological activity of the cannabinoids, at least one antibacterial agent, and at least one antifungal agent, as well as means of delivery of wound management composition and kits.
The foreign patent publication no. WO2019202356A1 refers to the composition with cannabidiol supplementation and anti-inflammatory herbal extracts that inhibit COX (cyclooxygenase) and LOX (lipoxygenase), Psoralea Corylifolia or Betulin or rosemary leaf extract or licorice extract (Glycyrrhiza Glabra) with a small amount of cannabidiol of not more than 1.0% by volume. The therapeutic effect of each herbal extract contains ingredients that can be used to heal skin inflammation.
As mentioned above, it is seen that pharmaceutical composition or products containing different herbs are used to treat different wounds to meet the needs of symptoms and wounds. The inventor has invented a chemical compositions that contain active substances from cannabis or hemp for inhibiting bacteria that affects the skin in order to heal wounds, inhibit bacterial infection, help the blood to clot in order to allow the wounds to heal, and result in quick-drying and inhibiting skin irritation, particularly suitable for patients with low immunity, such as those with diabetes, shingles, and patients after surgery, etc.
Summary of the Invention
The cannabinoid-based compositions are developed to provide unique properties to help the blood clot including the inhibition of bacterial infection. The aforementioned compositions comprise active substances from cannabis or hemp together with active substances from other genera in appropriate quantities. The preparation process of the aforementioned compositions involves the extraction and purification of the compositions to be chemical compositions suitable for healing and wound healing, especially for patients with bacterial skin infection, herpesvirus, psoriasis, postoperative wounds, diabetic wounds, skin imbalances and chronic inflammation.
The purpose of this invention is to provide a cannabinoid-based composition for medical use. The unique property of such composition is function in coagulating blood together with inhibiting bacterial infection, which directly affects the healing of wounds, reducing inflammation and wound pain that may spread and damage the tissues of the wound. This makes the wound heal and the wound is covered to prevent getting pathogens faster.
Detailed Description of the Invention
The cannabinoid-based compositions for medical use contain active substances from cannabis or hemp that are effective against gram-positive, gram-negative bacteria and fungi that cause skin infections and can help reduce inflammation together with the composition of active substances of anisic acid, flavonoids, and triterpenoids that can be found from Siam weed leaves, False daisy leaves, centella asiatica, nutgall, etc., which are characterized in that they help stop bleeding, increase blood clotting to prevent and reduce blood loss from wounds, inhibit skin irritation and improve the effectiveness of wound healing, including reducing scarring.
The cannabinoid-based compositions include:
The appropriate amount of active substances from cannabis or hemp is 20-80% by weight, together with the active substances from other genera in the appropriate amount of 20-80% by weight.
The preparation process of such composition requires the extraction process with hexane, ethyl acetate or other polar solvents such as acetone, ethanol, methanol, or water or a supercritical fluid extraction method, and then, to obtain a chemical mixture, it is subjected to a purification process by precipitation.
Active substances from cannabis or hemp may be selected from any one or more of cannabinoids comprising tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV) and cannabi di varin (CBDV), in combination thereof. Active substances from other genera may be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol, coumarin, false daisy leaves (Eclipta prostrata (L.) leaves, centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid, in combination thereof.
Research results of synergistic reaction properties of cannabinoid, anisic acid, flavonoid, and triterpenoids were obtained by testing a wide range of patients, such as those with diabetes, shingles, and patients after surgery, with the cannabinoid-based composition for inhibition of skinaffecting bacteria at appropriate total concentrations. In this study, 34 patients were treated in 6 groups, 16 of which were bedridden wounds, 5 with diabetic ulcers, 9 with fresh wounds, 2 with skin and subcutaneous tendon infections, 1 with herpetic wounds, and 1 with psoriasis.
According to the research, the compositions were sent to the accredited laboratory for testing (In Vitro) to test their activity against bacteria and virus and they were found to have a beneficial effect on inhibiting gram-positive skin bacteria and herpesvirus with low concentrations for the production of the compositions for use in the treatment of patients by choosing to develop into a cream or gel form for ease of use, storage, and portability of users and with appropriate concentrations to test the side effects of skin wounds and surrounding wounds. All wounds were healed from the use of the compositions in a shorter time than patients expected compared to the length of time that patients had been treated with other medicines prior to receiving the compositions in this study, and there were no adverse effects on the wound healing and other surrounding skin as shown in the table:
Figure imgf000006_0001
In conclusion, the cannabinoid-based composition in cream or gel form can be used to treat patients with bacterial skin infection, herpesvirus, psoriasis, postoperative wounds, diabetic wounds, skin imbalances and chronic inflammation. It was observed that the rapid response phase of blood coagulation and wound healing improved within 3 to 7 days, and treatment was completed within 2-8 weeks, depending on the individual patient's condition. However, all of them recovered from the use of this composition in a shorter time than patients expected compared to the length of time patients were treated with other medicines before receiving the medicines in this study and had no side effects on the wound and other surrounding areas. As the cannabinoid-based compositions comprise active substances that provide a direct effect on healing and inhibiting pathogens, balancing the skin system, and immune system, reducing inflammation, and reducing pain, through the endocannabinoid system and a group of ion channels on the cell membrane, TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation, the patients and their caregivers may use them to support patient care in conjunction with the current mainstream treatment. They also reduce the chance of organ loss such as in the feet and legs. In the case of patients with diabetic foot, they will recover faster and have fewer side effects from the disease. These are significant parts of gaining opportunities and holistic quality of life for patients and their caregivers. Best Mode of the Invention
As described in Detailed Description of the Invention section.

Claims

Claims
1. The cannabinoid-based compositions comprising active substances from cannabis and/or hemp together with active substances from other genera, which are characterized in that they stop bleeding and help the blood clot.
2. The cannabinoid-based compositions according to claim 1, wherein the appropriate concentration of active substances from cannabis and/or hemp is 20-80% by weight.
3. The cannabinoid-based compositions according to claim 1, wherein the appropriate concentration of active substances from other genera is 20-80% by weight.
4. The cannabinoid-based compositions according to claim 1 , wherein the active substances from cannabis and/or hemp can be selected from any one or more of cannabinoids containing tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol. (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) in combination thereof.
5. The cannabinoid-based compositions according to claim 1, wherein the active substances from other genera can be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol, coumarin, false daisy leaves (Eclipta prostrata (L.) leaves), centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid in combination thereof.
6. The cannabinoid-based compositions comprising active substances from cannabis and/or hemp combined with active substances from other genera, which are characterized in that they help inhibit skin irritation.
7. The cannabinoid-based compositions according to claim 6, wherein the appropriate concentration of active substances from cannabis and/or hemp is 20-80% by weight.
8. The cannabinoid-based compositions according to claim 6, wherein the appropriate concentration of active substances from other genera is 20-80% by weight.
9. The cannabinoid-based compositions according to claim 6, wherein the active substances from cannabis and/or hemp can be selected from any one or more of cannabinoids containing tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol. (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) in combination thereof.
10. The cannabinoid-based compositions according to claim 6, wherein the active substances from other genera can be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol, coumarin, false daisy leaves (Eclipta prostrata (L.) leaves), centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid in combination thereof.
11. The cannabinoid-based compositions comprising active substances from cannabis and/or hemp together with active substances from other genera, which are characterized in that they inhibit bacteria.
12. The cannabinoid-based compositions according to claim 11, wherein the appropriate concentration of active substances from cannabis and/or hemp is 20-80% by weight.
13. The cannabinoid-based compositions according to claim 11 , wherein the appropriate concentration of active substances from other genera is 20-80% by weight.
14. The cannabinoid-based compositions according to claim 11, wherein the active substances from cannabis and/or hemp can be selected, from any one or more of cannabinoids containing tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol. (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) in combination thereof.
15. The cannabinoid-based compositions according to claim 11, wherein the active substances from other genera can be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol coumarin, false daisy leaves (Eclipta prostrata (L.) leaves), centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid in combination thereof.
16. The cannabinoid-based compositions comprising active substances from cannabis and/or hemp together with active substances from other genera, which are characterized in that they reduce inflammation and muscle pain.
17. The cannabinoid-based compositions according to claim 16, wherein the appropriate concentration of active substances from cannabis and/or hemp is 20-80% by weight.
18. The cannabinoid-based compositions according to claim 16, wherein the appropriate concentration of active substances from other genera, is 20-80% by weight.
19. The cannabinoid-based compositions according to claim 16, wherein the active substances from cannabis and/or hemp can be selected from any one or more of cannabinoids containing tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol. (CBG), cannabivarin (CBV), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) in combination thereof.
20. The cannabinoid-based compositions according to claim 16, wherein the active substances from other genera can be selected from any one or more of active substances from Siam weed leaves (Chromolaena odorata (L.) leaves), anisic acid, flavonoid, isosakuranetin, odoratin, eupatol, coumarin, false daisy leaves (Eclipta prostrata (L.) leaves), centella asiatica (Linn.), asiatic acid, asiaticosides, and madecassic acid, madecassol, nutgall extract (Quercus infectoria Olivier), tannin, gallotannin, gallic acid, ellagic acid or phenolic acid in combination thereof.
PCT/TH2022/000032 2022-09-01 2022-09-01 Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates Ceased WO2024049361A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022476802A AU2022476802A1 (en) 2022-09-01 2022-09-01 Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates
PCT/TH2022/000032 WO2024049361A1 (en) 2022-09-01 2022-09-01 Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TH2022/000032 WO2024049361A1 (en) 2022-09-01 2022-09-01 Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates

Publications (1)

Publication Number Publication Date
WO2024049361A1 true WO2024049361A1 (en) 2024-03-07

Family

ID=84331575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TH2022/000032 Ceased WO2024049361A1 (en) 2022-09-01 2022-09-01 Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates

Country Status (2)

Country Link
AU (1) AU2022476802A1 (en)
WO (1) WO2024049361A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019155337A1 (en) * 2018-02-06 2019-08-15 Scicann Therapeutics Inc. Compositions comprising a cannabinoid and punicalagin and methods of use thereof
WO2019202356A1 (en) 2018-04-17 2019-10-24 Cebadex SE The enhancing effect of cannabidiol (cbd) to anti-inflammatory plant extracts having a dual inhibitory effect on cox and lox
US20210077422A1 (en) * 2019-03-19 2021-03-18 Spirit Songs Botanicals Cannabinoid formulation including synergistic organosulphur compounds
US20210236687A1 (en) 2020-01-31 2021-08-05 Pac-Dent, Inc. Cannabinoid-based oral hemostatic compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019155337A1 (en) * 2018-02-06 2019-08-15 Scicann Therapeutics Inc. Compositions comprising a cannabinoid and punicalagin and methods of use thereof
WO2019202356A1 (en) 2018-04-17 2019-10-24 Cebadex SE The enhancing effect of cannabidiol (cbd) to anti-inflammatory plant extracts having a dual inhibitory effect on cox and lox
US20210077422A1 (en) * 2019-03-19 2021-03-18 Spirit Songs Botanicals Cannabinoid formulation including synergistic organosulphur compounds
US20210236687A1 (en) 2020-01-31 2021-08-05 Pac-Dent, Inc. Cannabinoid-based oral hemostatic compositions

Also Published As

Publication number Publication date
AU2022476802A1 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
Oguntibeju Medicinal plants and their effects on diabetic wound healing
Davis et al. Wound healing. Oral and topical activity of Aloe vera
RU2750286C2 (en) Composition for local application stimulating wound healing
Jamil et al. Review effect of aloe vera on wound healing: Review: Effect of aloe vera on wound healing
EP4093393A1 (en) Compositions and methods for treatment of inflammatory conditions and diseases of the skin
CN111686152B (en) External composition for treating lymphedema, gel and preparation method thereof
Elegbede et al. Effect of fermented and green Aspalathus linearis extract loaded hydrogel on surgical wound healing in Sprague Dawley rats
AU2020103238A4 (en) A formulation for treatment of diabetic complications and method of preparation thereof
WO2006076844A1 (en) Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof
Ukwueze et al. Evaluation of the cutaneous wound healing activity of solvent fractions of Chromolaena odorata Linn
WO2008150246A1 (en) Herbal haemostatic composition
WO2024049361A1 (en) Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates
CN100353996C (en) Medicine composition for treating soft tissue damage and osteoarthropathy and its prepn process
Ullah et al. Medicinal plants: an insight into wound healing: medicinal plants & wound healing
Trieu et al. Wound-healing potential of topical application of preparations from Noni (Morinda citrifolia L.) leaf extract
CN105194330A (en) Traditional Chinese medicine composition for promoting wound healing and preparation method of traditional Chinese medicine composition
CN117338691A (en) Oil control composition and preparation method thereof
CN110787104A (en) Compound traditional Chinese medicine toothpaste and preparation method and application thereof
US11154583B2 (en) Composition and method of skin relief cream useful for eczema, psoriasis, lipoma, burn wounds, scars, keloids, shingles, dry skin disorders, and skin allergies
CN106902114A (en) A kind of pharmaceutical composition for treating acute soft tissue injury
Mohammad Histological and surgical study of the henna on wound healing in animals Field (Sheep)
CN101584746B (en) Pharmaceutical composition for wound healing and preparation method thereof
WO2007031364A1 (en) Dressing material comprising active substances
Yang et al. Wound healing activity of avocado peel ointment against second degree burn wound
Suksawat et al. Skin Ulcers as a Painful Disorder with Limited Therapeutic Protocols

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22802302

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2501003937

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: AU2022476802

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2022476802

Country of ref document: AU

Date of ref document: 20220901

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 22802302

Country of ref document: EP

Kind code of ref document: A1